BMX BioMaxima S.A.
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which include real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibiotics, agaroses and molecular biology media, media and buffers for in vitro cultures, phenotypic micromatrices, plastics and small equipment, basic substrate components, and form. In addition, it offers laboratory diagnostics solutions for various areas of clinical chemistry, haematology, coagulology, immunochemistry, POCT, rapid tests, and blood collection systems; and disposable materials comprising microbiology, dispensing equipment, tubes, plugs, tripods, capillaries, equipment, aspiration-vacuum system, containers, tank for analysers, urine analysis, microscope slides, reagent tubes, and autoclave equipment. BioMaxima S.A. was founded in 1997 and is headquartered in Lublin, Poland.…
Industry Peers
Diagnostics & ResearchKey Statistics
About BioMaxima (WSE: BMX)
›
BioMaxima (WSE: BMX) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 143 employees.
The shares were at 8.360 PLN on 19 November 2026, down 35.7% over 52 weeks. Its 52-week range is 8.360 PLN to 13.25 PLN, and it trades at the bottom of that range.
At a market capitalisation of 35.05M PLN, it trades at 39.8 times trailing earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a premium of 11% for BMX.
BioMaxima reports return on equity of 0.2%, an operating margin of 2.3% and revenue up 7.0% year over year.
Its debt exceeds its cash by 15.48M PLN, a debt-to-equity ratio of 0.30. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health.